TSI CEO to speak at annual US/China roundtable

TSI CEO to speak at annual US/China roundtable

  Zhou, co-founding partner and CEO to discuss market entry and development challenges in China.


Joe Zhou, TSI Group Ltd. co-founding partner and CEO, based in Shanghai, China, will be one of the featured speakers at the second annual US/China Roundtable to be held as a pre-NBJ Summit discussion on Tuesday, July 24 at the St. Regis Hotel in Dana Point, Calif. Zhou will focus on market entry and development challenges facing supplement, ingredient and beverage manufacturers seeking to penetrate the China health and wellness market.

According to Zhou, the future of dietary supplement manufacturing in China is very bright for the several reasons.

“China is already the largest supplier of the raw materials in the supplement industry and the quality standard of Chinese manufacturers has improved significantly in recent years,” says Zhou.

 “The Chinese are going to become a major supplement provider to the world and foremost brands around the world will come to China, bringing quality culture with it. Furthermore, it will increase Chinese manufacturers’ understanding of quality aspects of supplement manufacturing,” notes Zhou.

Zhou will discuss which product sectors in China have the most growth potential, and the market penetration of health and wellness per sales channel, product category and demographic.

The presentation also includes the best business approaches – B2B, B2C, or export/import.

TSI Group Ltd. is a Hong Kong registered global researcher, developer and manufacturer of ingredients and finished products with offices in the U.S., EU, Australia, Japan, and China. The North American division is based in Missoula, MT.

TSI Group Ltd. recently formed two strategic divisions – Value Services and Innovation Products to deliver sales and marketing to its clients worldwide. The innovation products division will provide global sales and marketing of proprietary branded ingredients such as PEAK ATP®, Promilin®, PromilinPro®, MSV60® and Ostivone®.

 “Our unique value services targeted to our global customers start with the raw materials we procure, then to granulations and drum-to-hopper formulations to solid dosage tablets and hard shell and soft gel capsules all completely integrated into one efficient, regulatory compliant and quality confirmed supply chain,” said Zhou.

The value services division branded ingredients will include PUREFLEX® Glucosamine and Chondroitin, GlucosaGreen™ non-shellfish Glucosamine, Phytovone™ soy extracts, Opteava® green tea and Gingko™ 24/6/5.

 Coupled with five existing ingredient manufacturing facilities and Q/C infrastructure platform in China, TSI also has several finished dose manufacturers under their umbrella with additional strategic investments in solid dosage manufacturing facilities that provide a well-established manufacturing base and total supply chain management according to Zhou.

TSI is strategically positioned to serve customers looking for a reliable Asian manufacturing partner to produce products that support brands entering the emerging Chinese market.

 Centered on the success of its customers, TSI believes its streamlined manufacturing and innovation model will provide substantial support and growth opportunities for the company and its customers.

“We have invested heavily in the development of innovative products and established strategic collaborations that will develop market changing products for our global customers,” Zhou said.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.